Drugmakers raised prices on hundreds of drugs despite Trump deals, Senate Democrats report finds - BERITAJA

President Donald Trump has repeatedly said his deals pinch drugmakers would bring down medicine supplier prices successful the U.S. But a study released by Senate Democrats finds prices person continued to climb — successful immoderate cases, sharply.

The study — released Thursday by Sen. Bernie Sanders, I-Vt., the ranking personnel connected the Senate Health, Education, Labor and Pensions Committee, up of a proceeding focused connected supplier prices — recovered that companies that signed supplier pricing deals pinch Trump person raised the costs of hundreds of medications and launched caller ones astatine an mean value of $353,000 a year.

The value hikes see costly cistron therapies, crab medications and aggregate sclerosis drugs.

The study besides said the companies that signed deals pinch Trump person made immense profits during his 2nd word successful office. In 2025, the companies made a mixed $177 cardinal successful profits, up from $107 cardinal the twelvemonth before.

It comes arsenic Health Secretary Robert F. Kennedy Jr. is group to attest Thursday successful back-to-back hearings connected Trump’s budget, first earlier the House Ways and Means Committee and later earlier the House Appropriations wellness panel. He is apt to look questions connected Trump’s priorities, including lowering medicine supplier costs.

The findings raise questions about whether the administration’s “most favored nation” deals — which Trump said would little U.S. supplier prices to lucifer those successful different able countries wherever narcotics are often acold little costly — are having a meaningful effect connected patients. The deals pinch the drugmakers were publicized by the White House, but specifications stay scant. It’s unclear whether the narcotics mentioned successful the caller study were a portion of the deals, though each of the drugmakers included were.

“One of the much frustrating aspects of caller supplier pricing announcements has been the deficiency of transparency into the alleged deals that are being made by the administration,” said Stacie Dusetzina, a wellness argumentation professor astatine Vanderbilt University successful Nashville, Tennessee. “In fact, erstwhile you excavation into the details, it appears that the administration’s efforts to day person mostly served to thief supplier companies.”

In an emailed statement, White House spokesperson Kush Desai said Sanders’ study “fixates connected medicine supplier database prices, which are meaningless because they do not bespeak the existent acquisition prices that patients salary astatine the drugstore counter.”

As a portion of the deals, drugmakers agreed to connection immoderate of their products for a discounted value for group paying pinch cash, not insurance, connected TrumpRx.gov, a discount medicine supplier platform. Many of the discounts are the aforesaid arsenic those recovered connected GoodRx, different discount site.

These discounts are abstracted from the database prices. And while group seldom salary the database value for a drug, a higher database value intends drugmakers could complaint security more.

The caller study pointed to respective blockbuster narcotics that saw database value hikes moreover arsenic companies were negotiating aliases signing deals pinch Trump.

For example, the database value of Keytruda, a wide utilized crab curen made by Merck, roseate by 6% to about $210,000 a twelvemonth successful the U.S., acold higher than prices successful countries for illustration Japan ($37,900) and France ($88,100), according to the report.

Novartis’ Kesimpta, a aggregate sclerosis drug, accrued by about $10,500 to $141,000 a year, according to the report. The yearly value of Kesimpta successful Germany is $17,300 and the yearly value successful Canada is $23,500.

The yearly database value of Opdivo, Bristol Myers Squibb’s immunotherapy, roseate 4% to $260,000, much than double the value successful different countries, including France ($90,300) and the United Kingdom ($113,000).

Merck, Novartis and Bristol Myers Squibb did not respond to a petition for comment.

Antonio Ciaccia, the CEO of 46brooklyn, a nonprofit group that tracks supplier pricing successful the U.S., said it’s been clear that the companies that signed deals pinch Trump did not work together to little prices crossed their full portfolio.

For galore of the narcotics not included successful the deals, it’s been “business arsenic accustomed and this twelvemonth is nary different,” he said.

He added that while mean brand-name database prices declined successful 2026 for the first time, that displacement was mostly driven by policies from the Biden administration, including Medicare supplier pricing negotiations.

The study besides recovered that companies that negotiated deals pinch Trump launched caller medications, galore of them crab drugs, pinch six- to seven-digit value tags.

According to the report, Johnson & Johnson’s crab supplier Inlexzo launched astatine a value of about $1 million; AbbVie’s crab supplier Emrelis is about $719,000; and AstraZeneca’s Datroway is about $419,000.

Novartis’ Itvisma, a one-time cistron therapy for spinal muscular atrophy, has a database value of about $2.59 million. Another cistron therapy from Novartis — Zolgensma, for spinal muscular atrophy — accrued by about $200,000 to much than $2.5 cardinal for a azygous people of treatment, according to the report.

Pfizer accrued the value of its lung crab supplier Vizimpro by about 5% to about $208,000 a year, according to the report.

Johnson & Johnson, AstraZeneca and Pfizer did not respond to a petition for comment. AbbVie declined to comment.